Session Title: Refractive II
Session Date/Time: Saturday 04/02/2012 | 08:30-11:00
Paper Time: 09:45
Venue: Grand Ballroom
First Author: : E.Mertens BELGIUM
Co Author(s): : P. Schraepen
Purpose:
The purpose of this study was to assess the efficacy, safety, intraocular pressure (IOP) and vault in patients who received the a new version of an implantable collamer lens to correct moderate to high myopia.
Setting:
Medipolis Eye Center, Antwerp, Belgium
Methods:
58 eyes of 30 patients underwent implantation of a myopic implantable collamer lens V4C model (STAAR Surgical Inc) for myopia correction. Mean spherical refraction was -6.17±1.39 diopters (D) (range: -3.50 to -8.75 D), and cylinder was ≤0.75D. Main outcomes measures evaluated during the retrospective study included: uncorrected distance visual acuity (UDVA), refraction, corrected distance visual acuity (CDVA), IOP and OCT vault. In addition, a subjective questionnaire about the frequency and severity of halos, glare, starburst or distortion was done. Target refraction was emmetropia in all cases. Mean anterior chamber depth (from endothelium) was 3.28±0.13 mm (range: 3.09 to 3.53) and mean IOP value was 15.11±2.70 mmHg (range: 10 to 20). RESULTS At 3 months both mean Snellen decimal UDVA and CDVA were 1.10±0.11, being the efficacy index 1.07. More than 80% of the eyes gained ≥1 lines of CDVA (safety index of 1.07). The treatment was highly predictable for myopia correction: residual refractive error was 0 D in all eyes and 100% of the eyes were within ±0.50 D of the attempted refraction. Mean IOP value was 11.17±1.72 mmHg (range: 9 to 14) and mean OCT vault was 355±82.2 µm (range: 280 to 482).
Conclusions:
Avoiding iridotomies and iridectomies while implanting posterior chamber phakic IOLs is a major step forward in refractive surgery. The overall performance was not altered in respect to prior models. The results of the present study support the efficacy and safety of the V4c myopic implantable collamer lens to treat moderate to high myopia.
Financial Disclosure:
... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented
